• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Cancer immunotherapy-related adverse events: causes and challenges

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Blidner, A. G.
    Choi, J.
    Cooksley, Timothy J
    Dougan, M.
    Glezerman, I.
    Ginex, P.
    Girotra, M.
    Gupta, D.
    Johnson, D.
    Shannon, V. R.
    Suarez-Almazor, M.
    Rapoport, B. L.
    Anderson, R.
    Show allShow less
    Affiliation
    Laboratory of Immunopathology, Institute of Biology and Experimental Medicine-CONICET, Buenos Aires, Argentina.
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    Despite the success and ongoing promise of monoclonal antibody-targeted immune checkpoint inhibitor immunotherapy of advanced malignancies, in particular, antibodies directed against CTLA-4 and PD-1/PD-L1, the development of immune-related adverse events (irAEs) remains a constraint of this type of therapy. Although rarely fatal, the occurrence of irAEs may necessitate discontinuation of immunotherapy, as well as administration of corticosteroids or other immunosuppressive therapies that may not only compromise efficacy but also predispose for development of opportunistic infection. Clearly, retention of efficacy of immune checkpoint-targeted therapies with concurrent attenuation of immune-mediated toxicity represents a formidable challenge. In this context, the current brief review examines mechanistic relationships between these events, as well as recent insights into immunopathogenesis, and strategies which may contribute to resolving this issue. These sections are preceded by brief overviews of the discovery and functions of CTLA-4 and PD-1, as well as the chronology of the development of immunotherapeutic monoclonal antibodies which target these immune checkpoint inhibitors.
    Citation
    Blidner AG, Choi J, Cooksley T, Dougan M, Glezerman I, Ginex P, et al. Cancer immunotherapy�related adverse events: causes and challenges. Supportive Care in Cancer. 2020.
    Journal
    Supportive Care in Cancer
    URI
    http://hdl.handle.net/10541/623228
    DOI
    10.1007/s00520-020-05705-5
    PubMed ID
    32857220
    Additional Links
    https://dx.doi.org/10.1007/s00520-020-05705-5
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1007/s00520-020-05705-5
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    • Authors: Anderson R, Theron AJ, Rapoport BL
    • Issue date: 2019
    • Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    • Authors: De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D
    • Issue date: 2018 Jun
    • New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    • Authors: Elia G, Ferrari SM, Galdiero MR, Ragusa F, Paparo SR, Ruffilli I, Varricchi G, Fallahi P, Antonelli A
    • Issue date: 2020 Jan
    • [Toxicity of immune checkpoints inhibitors].
    • Authors: Delaunay M, Caron P, Sibaud V, Godillot C, Collot S, Milia J, Prévot G, Mazières J
    • Issue date: 2018 Dec
    • The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    • Authors: Ruste V, Goldschmidt V, Laparra A, Messayke S, Danlos FX, Romano-Martin P, Champiat S, Voisin AL, Baldini C, Massard C, Laghouati S, Marabelle A, Lambotte O, Michot JM
    • Issue date: 2021 Nov
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.